Page 260 - Vitamin D and Cancer

10 Vitamin D and Prostate Cancer 247

127. Osborn JL, Schwartz GG, Smith DC et al (1995) Phase II trial of oral 1, 25-dihydroxyvitamin
D (calcitriol) in hormone refractory prostate cancer. Urol Onc 1:195–198
128. Gross C, Stamey T, Hancock S et al (2039) Treatment of early recurrent prostate cancer with
1,25-dihydroxyvitamin D3 (calcitriol). J Urol 159:2035, discussion 2039–2040
129. Smith DC, Johnson CS, Freeman CC et al (1999) A Phase I trial of calcitriol (1, 25-dihydroxy-
cholecalciferol) in patients with advanced malignancy. Clin Cancer Res 5:1339–1345
130. Beer TM, Munar M, Henner WD (2001) A Phase I trial of pulse calcitriol in patients with refrac-
tory malignancies: pulse dosing permits substantial dose escalation. Cancer 91:2431–2439
131. Muindi JR, Peng Y, Potter DM et al (2002) Pharmacokinetics of high-dose oral calcitriol:
results from a phase 1 trial of calcitriol and paclitaxel. Clin Pharmacol Ther 72:648–659
132. Muindi JR, Potter DM, Peng Y et al (2005) Pharmacokinetics of liquid calcitriol formulation
in advanced solid tumor patients: comparison with caplet formulation. Cancer Chemother
Pharmacol 56:492–496
133. Beer TM, Javle M, Lam GN et al (2005) Pharmacokinetics and tolerability of a single dose
of DN-101, a new formulation of calcitriol, in patients with cancer. Clin Cancer Res
11:7794–7799
134. Beer TM, Javle M, Henner WD et al (2004) Pharmacokinetics (PK) and tolerability of
DN-101, a new formulation of calcitriol, in patients with cancer. Proc Am Assn Cancer Res
45:91
135. Flaig TW, Barqawi A, Miller G et al (2006) A phase II trial of dexamethasone, vitamin D,
and carboplatin in patients with hormone-refractory prostate cancer. Cancer 107:266–274
136. Morris MJ, Smaletz O, Solit D et al (2004) High-dose calcitriol, zoledronate, and dexame-
thasone for the treatment of progressive prostate carcinoma. Cancer 100:1868–1875
137. Fakih MG, Trump DL, Muindi JR et al (2007) A phase I pharmacokinetic and pharmacodynamic
study of intravenous calcitriol in combination with oral gefitinib in patients with advanced solid
tumors. Clin Cancer Res 13:1216–1223
138. Beer TM, Lemmon D, Lowe BA et al (2003) High-dose weekly oral calcitriol in patients
with a rising PSA after prostatectomy or radiation for prostate carcinoma. Cancer
97:1217–1224
139. Beer TM, Eilers KM, Garzotto M et al (2003) Weekly high-dose calcitriol and docetaxel in
metastatic androgen-independent prostate cancer. J Clin Oncol 21:123–128
140. Beer TM, Ryan CW, Venner PM et al (2007) Double-blinded randomized study of high-dose
calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent
prostate cancer: a report from the ASCENT Investigators. J Clin Oncol 25:669–674
141. Trump DL, Potter DM, Muindi J et al (2006) Phase II trial of high-dose, intermittent calcitriol
(1, 25 dihydroxyvitamin D3) and dexamethasone in androgen-independent prostate cancer.
Cancer 106:2136–2142
142. Tiffany NM, Ryan CW, Garzotto M et al (2005) High dose pulse calcitriol, docetaxel and estra-
mustine for androgen independent prostate cancer: a phase I/II study. J Urol 174:888–892
143. Beer TM, Garzotto M, Katovic NM (2004) High-dose calcitriol and carboplatin in metastatic
androgen-independent prostate cancer. Am J Clin Oncol 27:535–541
144. Kissmeyer AM, Binderup E, Binderup L et al (1997) Metabolism of the vitamin D analog
EB 1089: identification of in vivo and in vitro liver metabolites and their biological activities.
Biochem Pharmacol 53:1087–1097
145. Bouillon R, Verstuyf A, Verlinden L et al (1995) Non-hypercalcemic pharmacological
aspects of vitamin D analogs. Biochem Pharmacol 50:577–583
146. Bouiloon R, Okamura WH, Norman AW (1995) Structure-function relationships in the
vitamin D endocrine system. Endocr Rev 16:200–257
147. Gulliford T, English J, Colston KW et al (1998) A phase I study of the vitamin D analogue
EB 1089 in patients with advanced breast and colorectal cancer. Br J Cancer 78:6–13
148. Dalhoff K, Dancey J, Astrup L et al (2003) A phase II study of the vitamin D analogue
Seocalcitol in patients with inoperable hepatocellular carcinoma. Br J Cancer 89:252–257
149. Evans TR, Colston KW, Lofts FJ et al (2002) A phase II trial of the vitamin D analogue
Seocalcitol (EB1089) in patients with inoperable pancreatic cancer. Br J Cancer 86:680–685